Bioventus (BVS) Depreciation & Amortization (CF) (2020 - 2026)

Bioventus (BVS) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $11.2 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 5.56% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.4 million (down 6.62% YoY) and the FY2025 annual result came in at $47.0 million, down 5.13% from the prior year.
• Depreciation & Amortization (CF) eased to $11.2 million in Q1 2026, from $11.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $16.9 million in Q4 2022 to a low of $11.2 million in Q1 2026.
• A 5-year average of $13.0 million and a median of $12.4 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 73.71% — and 2024, when it retreated 28.46%.
• Tracing BVS's Depreciation & Amortization (CF) over 5 years: stood at $16.9 million in 2022, then dropped by 26.43% to $12.5 million in 2023, then decreased by 0.48% to $12.4 million in 2024, then decreased by 5.73% to $11.7 million in 2025, then decreased by 4.18% to $11.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $11.2 million (Q1 2026), $11.7 million (Q4 2025), and $11.4 million (Q3 2025), per Business Quant data.